Colin advises clients throughout their lifecycle (all the way from start-up/spin-out to multinational listed companies) on the commercialisation of their intellectual property rights. In particular, advising on licensing deals, collaborations and R&D projects, distribution and manufacturing and the IP, commercial and regulatory aspects of M&A, VC investments and IPOs.

Having a 1st class degree in Cell Biology his practice has naturally become focused on the life sciences, healthcare and technology (with a particular focus on med-tech and clean-tech) sectors.

CV ansehen CV ausblenden

Aktuelle News & Insights

Life Sciences & Gesundheitswesen

Word on the street at the J.P. Morgan Healthcare Conference 2024

17. Januar 2024
In-depth analysis

von mehreren Autoren

Klicken Sie hier für Details
Private Equity

Advising Essential Pharma on its acquisition of European rights to Colobreathe®

12. Januar 2024

von mehreren Autoren

Klicken Sie hier für Details
Life Sciences & Gesundheitswesen

Advising gene therapy company AlveoGene on its complex spinout and launch investment

23. Oktober 2023

von mehreren Autoren

Klicken Sie hier für Details
Life Sciences & Gesundheitswesen

Theramex enters into an exclusive licensing agreement with Radius Health Inc to commercialise ELADYNOS®

9. März 2023

von Colin McCall und Charlie Adams

Klicken Sie hier für Details

Meet me at

Alle Veranstaltungen und Webinare finden Sie auf unserer Event-Seite.